ELEKTA ANNOUNCES FIRST LINEAR ACCELERATOR ORDER IN NEW ZEALAND

ELEKTA ANNOUNCES FIRST LINEAR ACCELERATOR ORDER IN NEW ZEALAND

Press Release 
Stockholm, Sweden, April 25, 2008


Elekta, a world leader in clinical solutions for radiosurgery and radiation
therapy, has finalized its first-ever New Zealand order. Auckland Radiation
Oncology Limited (ARO) have decided to invest in a new Elekta Synergy® system
with MOSAIQ™ EMR and Elekta VMAT, for delivery in April.

Andrew Wong, M.D., says ARO's decision to purchase Elekta was based on several
factors. “Elekta Synergy technology is state of the art. The 3D cone-beam
imaging performed at the time of treatment assures not only high-quality images
but also exceptional precision in treating tumors. An additional consideration
was Elekta's willingness to address ARO's questions and concerns with customized
service and support.”

ARO will be the first site in New Zealand to utilize Elekta Synergy which will
be also capable of performing Volumetric Modulated Arc Therapy (VMAT). This
advanced cancer treatment technology improves on Intensity Modulated Radiation
Therapy (IMRT) by simultaneously controlling the position and speed of the
linear accelerator gantry, the multileaf collimator and the dose rate, enabling
highly conformal radiation doses to the target site, while sparing surrounding
healthy tissue.

Elekta VMAT significantly reduces treatment times, with most treatments
completed in a remarkable three minutes or less. At the treatment control
console, clinicians at ARO will use Elekta's clinically proven 3D imaging
solution, X-Ray Volume Imaging (XVI), to obtain a low dose kilovoltage image,
then analyze and correct for submillimeter patient positioning and automatically
save all treatment information into the MOSAIQ™ electronic medical record
system.  

“Elekta VMAT is the fastest, most accurate radiation therapy on the market
today,” says Dr. Wong. “Our patients and staff will both benefit from the speed
of VMAT treatment times. Our first step is to implement an efficient Conformal
Therapy and IGRT program for our patients. Then we will advance upon that by
introducing VMAT”. 

ARO is New Zealand's first private radiotherapy center and is a joint venture
between MercyAscot and Southern Cross Hospitals. Dr. Wong explains, “The only
access to radiotherapy in New Zealand at present is through the public health
system. This can involve long waiting lists and patients being sent overseas for
treatment. ARO is focused on supplementing existing public healthcare, as well
as offering a premier private service to patients who would like a choice of
treatment options.”

The center is part of a comprehensive cancer center being developed by
MercyAscot which will be situated at the Mercy Hospital. Both organizations
share a mutual concern for people who do not have access to timely treatment in
the public healthcare system, and are hopeful that the cancer center will offer
an option that complements the treatment allowed by public health.

Dr. Wong says the new ARO center will treat mainly prostate and breast cancers.
“We are providing not only exemplary service and faster access to care but also
the very latest in advanced technology for treating cancer,” he says. 

******






For further information, please contact:

Brendan Vahey, Managing Director of Elekta Australia.
Tel: +61 2 9939 3255, e-mail: brendan.vahey@elekta.com  

Peter Ejemyr, Group VP Corporate Communications.
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 5,000 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With nearly 2,500 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.